SPY334.05-0.28 -0.08%
DIA273.26-0.64 -0.23%
IXIC11,079.82-28.25 -0.25%
新闻
DVAX
--
0.00%
--
Dynavax Q2 HBV vaccine sales plummet 68%
Dynavax (NASDAQ:DVAX) Q2 results: Total revenues: $2.7M (-67.5%); Heplisav-B sales: $2.4M (-67.5%). Net loss: ($51.6M); loss/share: ($0.53). Quick assets a
seekingalpha · 14小时前
Dynavax EPS misses by $0.29, misses on revenue
Dynavax (NASDAQ:DVAX): Q2 GAAP EPS of -$0.53 misses by $0.29. Revenue of $2.67M (-67.8% Y/Y) misses by $2.89M. Shares -1.8%. Press Release
seekingalpha · 14小时前
Current value of COVID-19 vaccine players overly bullish - Leerink
In a note, SVB Leerink warns that the current $115B aggregate valuation for COVID-19 vaccine developers is, unsurprisingly, overly optimistic. Analysts, le
seekingalpha · 16小时前
Dynavax Announces Second Quarter 2020 Financial Results
* Second quarter 2020 HEPLISAV-B® net product revenue of $2.4 million * Multiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications, including COVID-19 * Initial Phase 1 results from two COVID-
GlobeNewswire · 19小时前
Return On Capital Employed Overview: Dynavax Technologies
Dynavax Technologies (NASDAQ: DVAX) reported Q1 sales of $10.92 million. Earnings fell to a loss of $19.31 million, resulting in a 29.49% decrease from last quarter. Dynavax Technologies collected $10.57 million in revenue during Q4, but reported earnings show
Benzinga · 1天前
Why Dynavax's Stock Is Trading Higher Today
Dynavax Technologies (NASDAQ: DVAX) shares are trading higher on Monday after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to $250 million in milestone payments plus royalties on future
Benzinga · 3天前
Why Dynavax's Stock Is Trading Higher Today
Dynavax Technologies (NASDAQ: DVAX) shares are trading higher on Monday after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to $250 million in milestone payments plus royalties on future
Benzinga · 3天前
Dynavax Technologies shares are trading higher after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to $250 million in milestone payments plus royalties on future net sales.
Benzinga · 3天前
Dynavax divests its SD-101 oncology program to TriSalus Life Sciences
Seeking Alpha - Article · 3天前
TriSalus Life Sciences Acquires Dynavax's SD-101 Oncology Program In Purchase Agreement For Up To $250M In Milestone Payments Plus Royalties On Future Net Sales
SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide   TriSalus plans to further develop SD-101 as an oncology
Benzinga · 4天前
Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6
GlobeNewswire · 07/30 20:05
Will Dynavax Technologies (DVAX) Report Negative Q2 Earnings? What You Should Know
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Coronavirus Vaccine Development Puts These Stocks in Focus
Zacks · 07/28 13:19
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
Zacks · 07/27 14:53
Dynavax Technologies (DVAX) Stock Moves -0.3%: What You Should Know
Dynavax Technologies (DVAX) closed the most recent trading day at $10.12, moving -0.3% from the previous trading session.
Zacks · 07/23 21:50
Dynavax teams up with Medigen to develop COVID-19 vaccine
Dynavax (NASDAQ:DVAX) will collaborate with Taiwan's Medigen Vaccine Biologics Corp. (MVC) to develop an adjuvanted COVID-19 vaccine. The partnership will
seekingalpha · 07/23 17:29
Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
* Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018 * In preclinical testing, the combination generated strong virus neutralizing antibody responses * Medigen anticipates init
GlobeNewswire · 07/23 12:00
Dynavax Announces the Appointment of Two New Board Members
Ms. Julie Eastland, a strategic and financial executive with over 25 years of experience in biotechnology companiesMr. Brent MacGregor, a senior executive with over 20 years of.
GlobeNewswire · 07/21 20:10
OPK, NBEV, DVAX and ACAD among midday movers
Seeking Alpha - Article · 07/21 16:39
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59